Bone marrow angiogenesis in multiple myeloma
- 15 December 2005
- journal article
- review article
- Published by Springer Nature in Leukemia
- Vol. 20 (2) , 193-199
- https://doi.org/10.1038/sj.leu.2404067
Abstract
Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. It is induced by plasma cells via angiogenic factors with the transition from monoclonal gammopathy of undetermined significance (MGUS) to MM, and probably with loss of angiostatic activity on the part of MGUS. The pathophysiology of MM-induced angiogenesis is complex and involves both direct production of angiogenic cytokines by plasma cells and their induction within the microenvironment. The latter are secreted by stromal cells, endothelial cells (EC) and osteoclasts, and promote plasma cell growth, survival and migration, as well as paracrine cytokine secretion and angiogenesis in the bone marrow milieu. Angiogenesis is also supported by inflammatory cells following their recruitment and activation by plasma cells. Finally, circulating EC and endothelial precursor cells (EPC) contribute to the neovascularization, and the presence of EPC suggests that vasculogenesis (new vessel formation from EPC) may also contribute to the full MM vascular tree.Keywords
This publication has 63 references indexed in Scilit:
- Osteopontin, angiogenesis and multiple myelomaLeukemia, 2005
- Circulating endothelial progenitor cells in multiple myeloma: implications and significanceBlood, 2005
- Identification of genes modulated in multiple myeloma using genetically identical twin samplesBlood, 2004
- A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myelomaThrombosis and Haemostasis, 2004
- Do human myeloma cells directly produce basic FGF?Blood, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Multiple myeloma: evolving genetic events and host interactionsNature Reviews Cancer, 2002
- Bone marrow angiogenesis in patients with active multiple myelomaSeminars in Oncology, 2001
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994